frequencies (AF) of mutation, has been utilized to monitor treatment response. However, 20%-30% of patients yield no mutation from plasma genotyping despite deep sequencing depth, thus necessitating alternative monitoring method. The role of aberrant DNA methylation in the process of tumorigenesis both at individual genes and a genomewide scale has been well elucidated. We investigated the potential of DNA methylation as a biomarker for treatment monitoring. Method: We investigated the performance of mutation and DNA methylation as biomarkers to evaluate response to osimertinib using a DNA methylation panel consisting of 100,000 CpG sites and a targeted panel for mutation detection consisting of 168 lung cancer related genes with an average sequencing depth of 1,000x and 10,000x, respectively. Longitudinal plasma samples from 6 patients undergoing osimertinib were collected prior to treatment and at regular interval until disease progression, ranged from 6 to 9 times. Methylation level of a given sample was reflected by the percentage of significantly methylated blocks, which were significantly hypermethylated blocks comparing to healthy individuals. Results: All patients had EGFR sensitizing mutation and T790M at baseline. Four patients had additional concurrent mutations, including TP53, RB1, OR6F1 and BRCA2. At PD, all patients had detectable mutations except for one and 3 developed EFGR C797S. Four patients had at least two times of no detectable mutation during treatment. Among them, P05 and P06 had 5 and 6 times of no detectable mutation, respectively. In contrast, all patients had significantly methylated blocks detected at every point. In general, the trend of changes in mutation AF corresponds to the changes in the percentage of significantly methylated blocks in all patients except for one, who only had mutations detected at baseline and had consistently detectable DNA methylation at every point. Collectively, DNA methylation reached nadir at best response and gradually increased thereafter. An elevation of mutation AF or the emergence of new mutation(s) (molecular PD) was observed in 4 patients prior to PD assessed by imaging. In all patients, an elevation of DNA methylation was observed prior to PD assessed by imaging; among them, 3 had changes in DNA methylation prior to molecular PD, suggesting DNA methylation may be a more sensitive biomarker. Conclusion: Collectively, our study demonstrates DNA methylation, continuously increasing from the nadir (best response), can be utilized as a biomarker for treatment monitoring. Keyword: DNA methylation, treatment monitoring, advanced NSCLC Background: Most patients with non-small cell lung cancer (NSCLC) would have local or distant metastases at the time of diagnosis and lose the chance of cure. Currently, there is no reliable biomarker to predict the lymph node metastasis and prognosis of NSCLC. As an RNA-binding protein, the Musashi-2 gene blocks translation by binding to mRNA non-translated region and plays an important role in regulating biological procedures of cell. Existing studies have suggested that Musashi-2 protein associates with the development and poor prognosis of various solid tumors and was reported overexpressed in lung cancer tissue compared with normal lung tissue. Our study aimed to assess the role of Musashi-2 expression in lymph node metastasis and postoperative survival. Method: In this present study, immunohistochemistry (IHC) was performed to characterize expression of Musashi-2 protein in NSCLC patients who underwent radical
